Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has led the largest and most comprehensive analysis of the entire genomic landscape of the commonest type of blood cancer called chronic lymphocytic leukaemia (CLL) as part of the UK’s 100,000 Genomes Project. This work defines five genomic subgroups of CLL and associates these with clinical outcomes, and these subgroups provide a better estimation of patient prognosis than achieved by previous single gene analyses, allowing more tailored patient care.

digital illustration of a human DNA strand

A collaborative study led by the University of Oxford as part of the UK’s 100,000 Genomes Project, published in Nature Genetics, has defined five new subgroups of the most common type of blood cancer, chronic lymphocytic leukaemia (CLL) and associated these with clinical outcomes. This new method for risk stratifying patients could lead to more personalised patient care.

This is the first study to analyse all the relevant changes in DNA across the entire cancer genome, rather than targeted regions, to classify patients with cancer and link these subgroups to clinical outcomes.

Professor Anna Schuh of Oxford's Department of Oncology, who led the study, said: ‘We know that cancer is fundamentally a disease caused by changes in DNA that are acquired over the lifetime of an individual. The lab tools we currently use to predict whether or not a patient is likely to respond to a given therapy usually focus on single abnormalities in the cancer DNA and do not accurately predict the patient’s clinical outcome. This is why we asked the simple question: can we increase the precision of current testing by looking at all the acquired DNA changes in cancer at once?’

Read the full story on the Oxford Cancer website

Similar stories

300 companies created by the University of Oxford

The University of Oxford has reached the milestone of creating 300 companies based on research and ideas from students, staff and alumni.

What’s your sound barrier? New study finds nearly one in five people in the UK find everyday sounds intolerable

Researchers from King’s College London and University of Oxford have shown that 18.4 per cent of the general UK population report that certain sounds, such as loud chewing, and repetitive sniffing, cause a significant problem in their lives. The condition is known as misophonia.

Misophonia: nearly one in five UK adults have the condition causing extreme reactions to certain sounds

Many of us have sounds that we find to be annoying. But for some people, certain sounds actually trigger extreme reactions.

Any type of hormonal contraceptive may increase risk of breast cancer

An analysis of data by researchers at the Nuffield Department of Population Health’s Cancer Epidemiology Unit has shown that use of progestogen-only hormonal contraceptives is associated with a 20-30% higher risk of breast cancer. The results are published in PLOS Medicine.

Viewing self-harm images on the internet and in social media usually causes harm, according to new review

Clinical researchers have reviewed the international research evidence regarding the impact of viewing images of self-harm on the internet and in social media.